,11 More importantly, KRAS mutations have been found to directly interact with the tumor microenvironment (TME) and affect immunogenicity.12, 13, 14 Nevertheless, the prognostic and predictive significance of KRAS mutations in the context of real-world outcomes after different ICB-containing treatment regimens remains unclear, and several ongoing trials are evaluating the impact of KRAS mutations on response to treatment with ICB.15 Here, KRAS is linked to neoplasm.